| Bioactivity | CP-96021 is a potent and orally available leukotriene D4 (LTD4 Ki=34±5 μM) / platelet activating factor (PAF Ki=37±12 μM) receptor antagonist. CP-96021 has antagonist capable of simultaneously targeting two different inflammatory mediators, LTD4 and PAF. CP-96021 shows high specificity for α1, α2, β, dopamine-2, adenosine 1, 5-HT1, H1, muscarine, μ opioid, and GABA receptors, all expressing IC50 values greater than 10 μM. CP-96021 can be used to study the pathogenesis of many inflammatory diseases such as asthma[1]. |
| CAS | 139401-43-7 |
| Formula | C29H21FN4OS |
| Molar Mass | 492.57 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Marfat A, et al. The discovery of CP-96,021 and CP-96,486, balanced, combined, potent and orally active leukotriene D4 (LTD4)/platelet activating factor (PAF) receptor antagonists[J]. Bioorganic & Medicinal Chemistry Letters, 1995, 5(13): 1377-1382. |